Related Experiment Video
Updated: Jul 19, 2026
11:14
Mass Spectrometric Approaches to Study Protein Structure and Interactions in Lyophilized Powders
Published on: April 14, 2015
The changing structure of the pharmaceutical industry
1Boston University School of Management, USA.
Health Affairs (Project Hope)
|March 9, 2004
Summary
Pharmaceutical industry research and development (R&D) spending is rising due to the biotechnology sector
Area of Science:
- Biotechnology
- Pharmaceutical Industry
- Health Economics
Background:
- Industry structure changes, including the rise of biotechnology, are influencing pharmaceutical R&D expenditures.
- Biomedical market creation and vertical competition impact innovation and productivity.
- Concerns exist regarding potential socially wasteful spending and the weakening of academic science.
Purpose of the Study:
- To analyze the effects of industry structure changes on pharmaceutical R&D.
- To examine the dual impact of market creation and competition on innovation and potential drawbacks.
- To assess the sensitivity of R&D investment to cost containment measures.
Main Methods:
- Analysis of R&D expenditure trends.
- Examination of industry structure evolution.
- Assessment of market dynamics and competitive forces.
Main Results:
- Rising R&D expenditures are linked to the growth of the biotechnology sector.
- Increased competition may spur innovation but also lead to wasteful spending.
- R&D investment is increasingly sensitive to price controls and cost containment.
Conclusions:
- The evolving pharmaceutical landscape, driven by biotechnology, presents both opportunities for innovation and risks of inefficiency.
- Financial vulnerability of firms and complex contracts heighten R&D investment sensitivity to economic policies.
- Careful consideration of policy implications is needed to balance innovation incentives and societal costs.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...